CDK4/6-Based Drug Research and Development: A Four-Year Update
Miao-Xia Pu1, Wen-Bo Xu1, Li Ding2
1Pharmaceutical Research Institute, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, China.
Anti-Cancer Agents in Medicinal Chemistry
|July 28, 2026
Summary
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are vital cancer therapies, but drug resistance limits efficacy. Novel strategies like bifunctional molecules and PROTAC degraders show promise in overcoming resistance and improving long-term treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cyclin-dependent kinase 4/6 (CDK4/6) kinases regulate the cell cycle and are key targets in cancer therapy.
- Pharmacological inhibition of CDK4/6 is a cornerstone of modern cancer treatment, blocking G1-to-S phase transition.
- Acquired drug resistance to approved CDK4/6 inhibitors poses a significant challenge to long-term therapeutic efficacy.
Purpose of the Study:
- To systematically review recent advances (2022-2025) in CDK4/6 inhibitor research.
- To explore emerging therapeutic strategies, including bifunctional molecules and PROTAC-based protein degraders.
- To provide insights into next-generation therapies for overcoming drug resistance.
Main Methods:
- Systematic review of preclinical and clinical research on CDK4/6 inhibitors from 2022-2025.
- Focus on structural features, biological functions, and resistance mechanisms.
- Comprehensive exploration of novel therapeutic strategies like bifunctional agents and PROTACs.
Main Results:
- Conventional CDK4/6 inhibitor mechanisms are well-understood.
- Emerging strategies, including co-targeting (e.g., with HDAC, PARP1) and PROTACs, show promising preclinical results.
- Innovative approaches for drug resistance involve multi-target inhibition and induced protein degradation.
Conclusions:
- A deeper understanding of CDK4/6 inhibitors supports the design of next-generation therapies.
- Bifunctional agents and protein degraders offer promising avenues to overcome resistance.
- These advances are crucial for developing more effective and durable tumor treatments.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers
Published on: September 26, 2019
Related Concept Videos
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...